Champions Oncology, Inc. CSBR
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Champions Oncology, Inc. (CSBR) is a healthcare company listed in the US with a market value of about $65M. In the twelve months to July 31, 2026 it had revenue of $61M and net income of -$1M, a net margin of -1.8%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 8% a year, a 5-year average ROIC of -27%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 58% below the current price.
About Champions Oncology
Champions Oncology is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $9M in 2015 to $59M in 2026, growth of about 18.9% a year. It was profitable in 4 of the last 10 years in our data. Its share count rose by 2% over three years (dilution for shareholders). It spends 15% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Profit margin improving
- Strong R&D investment or growth above 20%
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $61M | $59M | $57M | $50M | $54M | $49M | $41M | $32M | $27M | $20M | $15M |
| Net income | -$1M | -$1M | $5M | -$7M | -$5M | $548000 | $362000 | -$2M | $128000 | -$1M | -$7M |
| Free cash flow | -$6M | -$5M | $7M | -$7M | $1M | $4M | -$5M | $685000 | $1M | -$2M | -$4M |
| EPS (diluted) | $-0.08 | $-0.08 | $0.33 | $-0.54 | $-0.39 | $0.04 | $0.02 | $-0.18 | $0.01 | $-0.13 | $-0.64 |
| Net margin | -1.8% | -2.0% | 8.3% | -14.5% | -9.9% | 1.1% | 0.9% | -6.5% | 0.5% | -7.3% | -44.7% |
| ROIC | — | -10.7% | 36.4% | -132.5% | -31.4% | 3.1% | 1.8% | -17.3% | 2.4% | -35655.3% | -1344.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Champions Oncology stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 58% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Champions Oncology pay a dividend?
Not currently.
Is Champions Oncology a good stock to buy?
We do not give buy or sell advice. Champions Oncology scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.